MELIE TIBURCIO: Open Payments
NPI 1215273149 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,386 in 61 payments from 14 companies in 2025. Trend: 2023 $1,931 · 2024 $1,868 · 2025 $1,386
Food & beverage: $1,386
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 9 | $288 |
| Novartis Pharmaceuticals Corporation | 14 | $276 |
| AstraZeneca Pharmaceuticals LP | 12 | $250 |
| CSL Behring | 6 | $169 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $88 |
| Daiichi Sankyo Inc. | 4 | $59 |
| ABBVIE INC. | 4 | $56 |
| SCPHARMACEUTICALS INC. | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 1 | $38 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
Products named: THORATEC HEARTMATE 3 LVAS IMPLANT KIT, LEQVIO, Kcentra, JARDIANCE, LOKELMA, FARXIGA, WAINUA, INJECTAFER.
Industry payments across NY — which companies pay providers there.
